Angelini Ventures
What do we look for?
Innovative and groundbreaking Series A and B companies in BioTech, TechBio, Connected Health Devices, Digital Diagnostics & Therapeutics, and Hybrid Care Platforms.
Our geographical focus is Europe and North America.
About Us
We are the venture capital firm established by Angelini Industries to invest in companies that positively impact human health
With 300 million € commitment and a diverse team operating globally, we support the innovation that will shape the future of care: we aim to build and support Digital Health and BioTech companies working to make healthcare smarter, using data to improve care and outcomes, and reinventing the patient journey.
What do we look for?
What's our commitment to your success?
A diverse global team with breadth and depth of expertise and access to local ecosystems and world leading experts. Financial resources and top-tier syndicate network to support our portfolio companies through multiple rounds.
A track record of success and experience navigating the ups and downs of company building. Our team members have:
- made significant contributions in drug development and academic research,
- deployed AI technology in clinical and commercial settings,
- taken products through regulatory approval, market launch and scaling commercial operations,
- founded and led companies in healthcare, taken companies public, exited through M&A transactions.
- access to Angelini Industries for synergies and opportunities.
We are part of one of Italy's great entrepreneurial success stories
Our passion for transforming healthcare, combined with Angelini Industries’ long history of innovation, both in the consumer and pharmaceutical space, make us uniquely qualified to identify critical areas of need and support the development of impactful solutions.
We believe collaboration is the connective tissue between innovation and execution. By aligning our venture investments with our enterprise focus on digital transformation and consumer-oriented solutions, we can change health care.
Prof. Sergio Marullo di Condojanni,